Gene editor CRISPR Therapeutics (CRSP +3.8%) and CRISPR/Cas9-focused biotech KSQ Therapeutics have inked reciprocal license agreements aimed at advancing cell therapies for cancer.
Under the terms of the respective contracts, CRSP
will receive non-exclusive access to KSQ’s intellectual property (IP)
for certain novel gene targets in its allogeneic oncology cell therapy
programs while KSQ will gain non-exclusive access to CRSP’s IP for
editing novel gene targets identified by KSQ as part of its eTIL
(engineered tumor infiltrating lymphocyte) cell programs.
Financial terms remain confidential.
https://seekingalpha.com/news/3505780-crispr-teams-ksq-therapeutics-cancer-shares-4-percent
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.